IL218018A0 - Novel n-substituted-pyrrolidines as inhibitors of mdm2-p-53 interactions - Google Patents
Novel n-substituted-pyrrolidines as inhibitors of mdm2-p-53 interactionsInfo
- Publication number
- IL218018A0 IL218018A0 IL218018A IL21801812A IL218018A0 IL 218018 A0 IL218018 A0 IL 218018A0 IL 218018 A IL218018 A IL 218018A IL 21801812 A IL21801812 A IL 21801812A IL 218018 A0 IL218018 A0 IL 218018A0
- Authority
- IL
- Israel
- Prior art keywords
- mdm2
- pyrrolidines
- interactions
- inhibitors
- substituted
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25141309P | 2009-10-14 | 2009-10-14 | |
| US34562610P | 2010-05-18 | 2010-05-18 | |
| PCT/EP2010/065159 WO2011045257A1 (en) | 2009-10-14 | 2010-10-11 | Novel n-substituted-pyrrolidines as inhibitors of mdm2-p-53 interactions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL218018A0 true IL218018A0 (en) | 2012-04-30 |
Family
ID=43567698
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL218018A IL218018A0 (en) | 2009-10-14 | 2012-02-09 | Novel n-substituted-pyrrolidines as inhibitors of mdm2-p-53 interactions |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US8017607B2 (enExample) |
| EP (1) | EP2488491A1 (enExample) |
| JP (1) | JP2013507416A (enExample) |
| KR (1) | KR20120081210A (enExample) |
| CN (1) | CN102548963A (enExample) |
| AU (1) | AU2010305914A1 (enExample) |
| BR (1) | BR112012008485A2 (enExample) |
| CA (1) | CA2774512A1 (enExample) |
| IL (1) | IL218018A0 (enExample) |
| IN (1) | IN2012DN02487A (enExample) |
| MX (1) | MX2012003982A (enExample) |
| WO (1) | WO2011045257A1 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8889632B2 (en) | 2007-01-31 | 2014-11-18 | Dana-Farber Cancer Institute, Inc. | Stabilized p53 peptides and uses thereof |
| EP2508531B1 (en) | 2007-03-28 | 2016-10-19 | President and Fellows of Harvard College | Stitched polypeptides |
| US8354444B2 (en) * | 2008-09-18 | 2013-01-15 | Hoffmann-La Roche Inc. | Substituted pyrrolidine-2-carboxamides |
| US20110118283A1 (en) * | 2009-11-17 | 2011-05-19 | Qingjie Ding | Substituted Pyrrolidine-2-Carboxamides |
| SI2603600T1 (sl) | 2010-08-13 | 2019-04-30 | Aileron Therapeutics, Inc. | Peptidomimetični makrocikli |
| WO2012076513A1 (en) * | 2010-12-09 | 2012-06-14 | F. Hoffmann-La Roche Ag | 3-cyano-1-hydroxymethyl-2-phenylpyrrolidine derivatives as inhibitors of mdm2-p53 interactions useful for the treatment of cancer |
| TR201807311T4 (tr) | 2011-03-10 | 2018-06-21 | Daiichi Sankyo Co Ltd | Dispiropirolidin derivesi. |
| TW201806968A (zh) | 2011-10-18 | 2018-03-01 | 艾利倫治療公司 | 擬肽巨環化合物 |
| KR102112373B1 (ko) | 2012-02-15 | 2020-05-18 | 에일러론 테라퓨틱스 인코포레이티드 | 펩티드모방체 마크로사이클 |
| HK1205454A1 (en) | 2012-02-15 | 2015-12-18 | Aileron Therapeutics, Inc. | Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles |
| TWI586668B (zh) | 2012-09-06 | 2017-06-11 | 第一三共股份有限公司 | 二螺吡咯啶衍生物之結晶 |
| WO2014071241A1 (en) | 2012-11-01 | 2014-05-08 | Aileron Therapeutics, Inc. | Disubstituted amino acids and methods of preparation and use thereof |
| WO2014100065A1 (en) | 2012-12-20 | 2014-06-26 | Merck Sharp & Dohme Corp. | Substituted imidazopyridines as hdm2 inhibitors |
| BR112017005598A2 (pt) | 2014-09-24 | 2017-12-12 | Aileron Therapeutics Inc | macrociclos peptidomiméticos e usos dos mesmos |
| JP2018503595A (ja) | 2014-09-24 | 2018-02-08 | エルロン・セラピューティクス・インコーポレイテッドＡｉｌｅｒｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | ペプチド模倣大環状分子およびその製剤 |
| WO2016154058A1 (en) | 2015-03-20 | 2016-09-29 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and uses thereof |
| US10023613B2 (en) | 2015-09-10 | 2018-07-17 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles as modulators of MCL-1 |
| CN109152843A (zh) | 2016-05-20 | 2019-01-04 | 豪夫迈·罗氏有限公司 | Protac抗体缀合物及其使用方法 |
| WO2022183006A1 (en) | 2021-02-25 | 2022-09-01 | Mayo Foundation For Medical Education And Research | Compounds for programmable protein degradation and methods of use for the disease treatment |
| WO2023056069A1 (en) | 2021-09-30 | 2023-04-06 | Angiex, Inc. | Degrader-antibody conjugates and methods of using same |
| WO2024240858A1 (en) | 2023-05-23 | 2024-11-28 | Valerio Therapeutics | Protac molecules directed against dna damage repair system and uses thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0947511A1 (en) | 1998-03-30 | 1999-10-06 | F. Hoffmann-La Roche Ag | Derivatives of phenoxy acetic acid and of phenoxymethyl tetrazole having antitumor activity |
| JP2003505388A (ja) | 1999-07-21 | 2003-02-12 | アストラゼネカ・アクチエボラーグ | 新規化合物 |
| WO2005099687A2 (en) | 2004-04-09 | 2005-10-27 | President And Fellows Of Harvard College | Analogs of salinosporamide a |
| US7423051B2 (en) | 2004-07-15 | 2008-09-09 | Hoffmann-La Roche Inc. | 2,6-diaminopyridine derivatives |
| AU2006216780B8 (en) | 2005-02-22 | 2010-04-22 | The Regents Of The University Of Michigan | Small molecule inhibitors of MDM2 and uses thereof |
| BRPI0710477A2 (pt) | 2006-01-18 | 2011-08-16 | Hoffmann La Roche | cis-4, 5- biarila - 2- imidazolinas heterocìclicas como inibidores da mdm2 |
| WO2008005268A1 (en) | 2006-06-30 | 2008-01-10 | Schering Corporation | Substituted piperidines that increase p53 activity and the uses thereof |
| CA2734363C (en) * | 2008-09-18 | 2016-10-25 | F. Hoffmann-La Roche Ag | Substituted pyrrolidine-2-carboxamides |
-
2010
- 2010-10-06 US US12/898,974 patent/US8017607B2/en not_active Expired - Fee Related
- 2010-10-11 WO PCT/EP2010/065159 patent/WO2011045257A1/en not_active Ceased
- 2010-10-11 KR KR1020127012100A patent/KR20120081210A/ko not_active Ceased
- 2010-10-11 EP EP10768450A patent/EP2488491A1/en not_active Withdrawn
- 2010-10-11 CN CN2010800461741A patent/CN102548963A/zh active Pending
- 2010-10-11 MX MX2012003982A patent/MX2012003982A/es not_active Application Discontinuation
- 2010-10-11 AU AU2010305914A patent/AU2010305914A1/en not_active Abandoned
- 2010-10-11 JP JP2012533592A patent/JP2013507416A/ja active Pending
- 2010-10-11 IN IN2487DEN2012 patent/IN2012DN02487A/en unknown
- 2010-10-11 BR BR112012008485A patent/BR112012008485A2/pt not_active IP Right Cessation
- 2010-10-11 CA CA2774512A patent/CA2774512A1/en not_active Abandoned
-
2012
- 2012-02-09 IL IL218018A patent/IL218018A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2010305914A1 (en) | 2012-03-08 |
| CN102548963A (zh) | 2012-07-04 |
| MX2012003982A (es) | 2012-05-08 |
| US20110086854A1 (en) | 2011-04-14 |
| BR112012008485A2 (pt) | 2019-09-24 |
| EP2488491A1 (en) | 2012-08-22 |
| WO2011045257A1 (en) | 2011-04-21 |
| CA2774512A1 (en) | 2011-04-21 |
| IN2012DN02487A (enExample) | 2015-08-28 |
| US8017607B2 (en) | 2011-09-13 |
| JP2013507416A (ja) | 2013-03-04 |
| KR20120081210A (ko) | 2012-07-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201700326B (en) | Inhibitors of beta-secretase | |
| ZA201006719B (en) | Substituted dihydropyrazolones as inhibitors of hif-prolyl-4-hydroxylases | |
| ZA201102892B (en) | Pyrazolylaminopyridines as inhibitors of fak | |
| EP2576552A4 (en) | BENZOQUINOLONE INHIBITORS OF VMAT2 | |
| ZA201206456B (en) | Uses of dgati inhibitors | |
| EP2249650A4 (en) | ANILINOPYRIDINE AS A FAK HEMMER | |
| IL223205B (en) | Crystal form of benzylbenzene inhibitor 2sglt | |
| EP2438246A4 (en) | CONSTRUCTION ASPECTS | |
| SG10201404913QA (en) | Inhibitors of cognitive decline | |
| IL217833A0 (en) | Inhibitors of cognitive decline | |
| SMT202100234T1 (it) | Usi di inibitori di fattori inducibili da ipossia | |
| PT2440558E (pt) | Compostos de dihidropirrolonaftirridinona como inibidores de jak | |
| IL217756A0 (en) | Inhibitors of jnk | |
| IL222474A0 (en) | Method of synthesis | |
| IL213935A0 (en) | Novel heterocyclic compounds as metap-2 inhibitors | |
| EP2591368A4 (en) | METHOD FOR DETERMINING ETHANOL CONSUMPTION | |
| IL214958A0 (en) | Novel uses of fibrinogen | |
| IL215486A0 (en) | Compositions of cholinesterase inhibitors | |
| EP2379502A4 (en) | NOVEL FORMS OF EPERISON | |
| LU91725B1 (en) | Novel uses of V-ATPASE inhibitors | |
| GB0908609D0 (en) | New use of isoQC inhibitors | |
| GB0915927D0 (en) | Novel inhibitors | |
| GB0905280D0 (en) | Novel uses of VEGFxxxb | |
| GB201003936D0 (en) | Novel inhibitors | |
| GB201003502D0 (en) | Novel inhibitors |